Cadrenal Therapeutics (NASDAQ: CVKD) Reports Q4 2025 Results and Provides Major Update on CAD-1005 Program

Key Highlights

• Encouraging Phase 2 Results for CAD-1005 in HIT: Cadrenal’s lead program, CAD-1005—a first-in-class selective 12-LOX inhibitor targeting heparin-induced thrombocytopenia (HIT)—delivered promising data in a randomized, blinded, placebo-controlled Phase 2 trial. Patients receiving CAD-1005 alongside standard anticoagulation experienced a greater than 25% absolute reduction in new or worsening thrombotic events versus placebo.
• Regulatory Progress: The company completed its End-of-Phase 2 (EOP2) meeting with the FDA on March 26, 2026, clarifying the potential registrational path for a planned Phase 3 pivotal trial of CAD-1005 in HIT. Incorporation of FDA feedback into the Phase 3 protocol is underway.
• Orphan Drug and Fast Track Designations: CAD-1005 continues to benefit from Orphan Drug and Fast Track status from the FDA, along with orphan designation from the European Medicines Agency, positioning it uniquely as the only selective 12-LOX inhibitor currently in clinical development for HIT.
• Ongoing R&D in Broader 12-LOX Platform: While HIT remains the near-term focus, Cadrenal is exploring the potential of 12-LOX inhibition for chronic conditions such as obesity and type 2 diabetes, with preclinical data indicating possible improvements in glycemic control, beta-cell preservation, and inflammatory signaling.

Financial Performance (Q4 and Full Year 2025)

• Q4 2025 R&D Expenses: \$0.7 million (down from \$1.5 million in Q4 2024)
• Q4 2025 General & Administrative Expenses: \$2.4 million (down from \$2.7 million in Q4 2024)
• Q4 2025 Net Loss: \$3.0 million (improved from \$4.2 million in Q4 2024)
• Year-End Cash Position: \$4.0 million as of December 31, 2025 (down from \$10.0 million at the end of 2024)
• Full-Year 2025 Net Loss: \$13.2 million (versus \$10.7 million in 2024)
• Shares Outstanding: Approximately 2.3 million as of December 31, 2025
• Company is actively evaluating financing and strategic alternatives to support upcoming clinical development, including the pivotal Phase 3 CAD-1005 trial.

What Investors Need to Know (Potential Share Price Impacts)

• Positive Phase 2 results and regulatory clarity around CAD-1005’s Phase 3 path are significant value drivers and could catalyze interest from institutional investors, partners, or acquirers in the rare disease and hematology spaces.
• The substantial reduction in thrombotic events and regulatory feedback from the FDA de-risk the program, increasing the probability of eventual approval and commercial success if replicated in Phase 3.
• Current cash runway appears limited, and additional financing is required for Phase 3 execution. Dilutive or non-dilutive funding events may impact the share price in the near term.
• Orphan Drug and Fast Track designations, as well as the competitive moat (being the only selective 12-LOX inhibitor in clinical development), bolster the program’s commercial prospects and potential for premium pricing.
• Broader pipeline opportunities in obesity, diabetes, and other thrombotic/immune conditions further enhance Cadrenal’s long-term value proposition.

Management Commentary

“CAD-1005 continues to reinforce our conviction that selective 12-LOX inhibition may offer a differentiated approach for patients with HIT, a life-threatening, immune-mediated prothrombotic disorder, and a serious condition with substantial unmet need. Despite modern care, mortality remains high (up to 18-20% in some groups), with many survivors facing limb amputations. The encouraging Phase 2 results, including the reduction in thrombotic events observed on top of standard anticoagulant therapy, further strengthen our confidence in the program and in the decision to make CAD-1005 our lead development priority.”

“The recent End-of-Phase 2 meeting with the FDA is an important milestone in clarifying the regulatory path forward for CAD-1005. As we incorporate FDA feedback and prepare for the next stage of development, we remain focused on advancing CAD-1005 as our lead priority in HIT. At the same time, we continue to evaluate longer-term opportunities across our broader 12-LOX platform and other pipeline assets to support future value creation.”

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing novel therapies for life-threatening immune and thrombotic conditions. Its lead asset, CAD-1005, is a first-in-class 12-LOX inhibitor for HIT, supported by Orphan Drug and Fast Track designations in the U.S. and orphan drug status in the EU. The company’s pipeline also includes tecarfarin, a late-stage oral vitamin K antagonist for chronic anticoagulation, and frunexian, a Factor XIa inhibitor for acute hospital settings.

Conclusion

The combination of strong Phase 2 data, positive regulatory momentum, and unique competitive positioning makes the CAD-1005 program a potentially transformative opportunity for Cadrenal Therapeutics and its shareholders. However, investors should closely monitor upcoming financing activities, as these will be critical to supporting the pivotal Phase 3 trial and driving long-term value.

Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Forward-looking statements, including those about clinical development, regulatory outcomes, and financial strategy, are subject to risks and uncertainties. Investors should refer to Cadrenal Therapeutics’ filings with the SEC for a complete discussion of risk factors and should consult their own advisors before making investment decisions.

View Cadrenal Therapeutics, Inc. Historical chart here